Evidence map›Paper›PMID 40346085›Full record

ArticleScientific reports2025

Anti-HBs persistence and anamnestic response among medical interns vaccinated in infancy.

Nesrine Fathi Hanafi, Nashwa Naguib Omar, Ghada Abdelwahed Ismail, Amani Ali El-Kholy, Ahmed ElShafei, Sara AbdelAziz Essa

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nesrine Fathi HanafiDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Nashwa Naguib OmarDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ghada Abdelwahed IsmailDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Amani Ali El-KholyDepartment of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Ahmed ElShafeiModern University for Information and Technology, Cairo, Egypt.
Sara AbdelAziz EssaDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. sara_aziz05@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medical interns are at high risk of acquiring Hepatitis B Virus (HBV) infection during their training. HBV vaccination is the most effective measure to reduce the global incidence of HBV. The duration of protection after HBV vaccination is still controversial. We aimed to determine the prevalence of protective anti-HBs levels among medical interns who had received compulsory hepatitis B vaccination in infancy, and to assess the anamnestic response of those subjects with non-protective antibodies titers, to a booster dose of the vaccine. We conducted a cross-sectional study on 519 medical interns in 2022. We examined their immunization status and records. Blood samples were collected and qualitative testing of Hepatitis B surface antigen (HBsAg), and quantitative testing of Hepatitis B surface antibody (anti-HBs) were performed. For medical interns whose titers were ˂ 10 mIU/mL, a booster dose of the vaccine was given, followed by repeat testing of anti-HBs 2 months later. About 304 (58.6%) of the medical interns revealed titers higher than or equal 10 mIU/mL. About (44.93%) of male medical interns showed an immunity level below 10 mIU/mL. However, (43.91%) of female medical interns had an antibody titer of 100 mIU/mL or higher. All subjects who got a booster dose presented a titer level of 10 mIU/mL 2 months later. About (41.4%) of our medical interns enrolled in the study had anti-HBs titer ˂ 10 mIU/mL. This raises the importance of establishing a screening protocol and offering booster dose for those at risk to protect them against the high risk of infection.

Indexed as

Hepatitis BHepatitis B AntibodiesHepatitis B VaccinesInternship and ResidencyAdultCross-Sectional StudiesFemaleHepatitis B Surface AntigensHepatitis B virusHumansImmunization, SecondaryInfantMaleVaccinationHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesBoosterEgyptHepatitis BImmunizationVaccine

Identifiers

PMID40346085
PMCPMC12064783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.